Danger being further info required e.g. Mesoblast AGVHD indication. Oncological Drugs Advisory Committee voted 9-1 in favour of the drugs efficacy, yet was denied by FDA after ph3 (statistically significant).
We're not using biomarkers, so they could say we don't understand the drugs mechanism of action well enough for it to be approved.
Nothing would surprise me with bureaucracies!
Share Price, page-153
-
- There are more pages in this discussion • 10,803 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.26 |
Change
0.155(0.77%) |
Mkt cap ! $2.607B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $1.642M | 80.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 144 | $20.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.26 | 52 | 5 |
View Market Depth
| Last trade - 14.31pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |